Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9Other hematologic neoplasm 5Breast 5Lymphoid 2Thoracic 1Plasma cell 1Other neoplasm 1Myeloid 1Head & Neck 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 2704Lung Neoplasms 2262Small Cell Lung Carcinoma 451Breast Neoplasms 394Neoplasms 348Colorectal Neoplasms 245Ovarian Neoplasms 208Pancreatic Neoplasms 196Melanoma 196Prostatic Neoplasms 187Adenocarcinoma of Lung 183Neoplasm Metastasis 177Head and Neck Neoplasms 175Mesothelioma, Malignant 152Esophageal Neoplasms 144Carcinoma, Renal Cell 142Stomach Neoplasms 141Colonic Neoplasms 138Urinary Bladder Neoplasms 124Mesothelioma 121Squamous Cell Carcinoma of Head and Neck 115Uterine Cervical Neoplasms 97Sarcoma 86Brain Neoplasms 86Kidney Neoplasms 82Carcinoma, Hepatocellular 71Liver Neoplasms 68Adenocarcinoma, Bronchiolo-Alveolar 68Rectal Neoplasms 64Pleural Effusion, Malignant 64

Interventions

Pemetrexed 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pathologic Complete Response × Thoracic × Clear all
NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡